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Atrial fibrillation is one of the major cardiovascular epidemics in the 21st century, causing 
ischemic strokes, heart failure, cardiovascular deaths, and unplanned hospitalizations. 1 Even 
on optimal management, cardiac deaths and unplanned cardiovascular hospitalisations are 
common in AF patients. Current management of patients with AF does not differentiate 
greatly between patients with different pathophysiological forms of the disease. 1  While 
these therapies  can prevent most strokes and improve quality of life, patients with AF are 
still at risk of cardiac deaths, often driven by heart failure or sudden death. 1, 2 The variable 
effect of interventions aimed at controlling rate and especially at controlling rhythm, 
suggests that an understanding of the different drivers of AF in specific patient groups could 
help devise better strategies for prevention and management of the disease. Devising better 
concepts to prevent incident and recurrent AF seems essential to contain the adverse 
cardiovascular consequences of AF. 
Cardiovascular risk factors have been well recognised to lead to the development and 
maintenance of AF. Recent studies have highlighted the marked structural and 
electrophysiological changes that occur within the atria in response to these risk factors such 
as hypertension and obesity.3 Their role in the AF disease process has also been observed 
with progression of the atrial myopathy even after successful ablation of AF. Indeed, even in 
individuals without established risk factors, there can be evidence of an atrial myopathy.4 
Thus, other, yet unidentified factors apparently lead to AF in these persons. 
It is in this context that the study by Dr Lee and colleagues provides exciting insights.5 Using 
a nationwide data set of healthy Koreans.excluding those with established cardiovascular 
diseases known to contribute to AF, this study identified factors associated with the first 
manifestation of AF. A strength of the cohort is the standardised acquisition of clinical data, 
including blood pressure and glucose tolerance, throughout this population as part of a 
National Health Check. Uniquely, the authors excluded patients with established (ICD-
coded) cardiovascular diseases known to increase AF risk, such as diabetes, established 
hypertension, heart failure, valvular heart disease, coronary artery disease, and others. 
Furthermore, patients with non-cardiac conditions that could be associated with AF, such as 
malignancy, pulmonary disease, or chronic rheumatoid diseases were excluded. This can 
only be done in very large cohorts with a long follow-up as this eliminates a subpopulation 
with a high risk for incident AF. In this healthy Korean population, the authors found that 
elevated diastolic blood pressure and an impaired fasting glucose were associated with an 
increased risk of atrial fibrillation. In addition, they confirmed findings by others that a high 
body mass index (BMI) is associated with atrial fibrillation. Further exploration of the data 
showed that these factors added independently to AF risk in patients with low or normal 
body mass index (BMI < 20 or BMI 20 – 25), while the effect was much less clear in the part 
of the population that was obese.  
Increasing age and body mass index have been proposed as driving the increased prevalence 
and incidence of AF. 2 Experimental data suggest that electrical isolation of atrial 
cardiomyocytes by infiltrating fat cells, cross-talk between activated adipocytes and atrial 
myocardium, and abnormal secretory activity of atrial cardiomyocytes creates a substrate for 
AF in obese persons. 3, 6 Recent work has clearly established that reducing weight and 
treating the associated risk factors can reduce symptoms related to AF, reduce AF burden 
and improve the maintenance of sinus rhythm – in some cases without the need for catheter 
ablation – in overweight and obese patients with AF.7, 8  
Hypertension remains the most common attributable risk for AF as a result of its prevalence 
within the community. Elevated blood pressure has been associated with slowing of atrial 
conduction due to formation of excessive extracellular matrix, and lowering of an elevated 
blood pressure has been suggested as an important intervention to prevent AF.9 The 
mechanisms that link elevated diastolic blood pressure to AF need further study, but they are 
likely related to increased wall pressure in the left atrium, structural change and activation of 
the renin-angiotensin-system and other fibrotic pathways. Interestingly, targeting blood 
pressure as an isolated risk factor in the clinic has yielded variable outcomes.10  
The mechanism linking impaired fasting glucose to AF are less clear. It is well established 
that obesity, especially extreme obesity, contributes to increased cellular glucose tolerance 
and diabetes. The data presented here identify a role of impaired fasting glucose in patients 
of normal weight for AF risk, potentially pointing to the heritable components of pre-
diabetes. Impaired fasting glucose will shift cellular metabolism, with potentially profound 
functional impacts in cells that require constant energy generation, such as cardiac cells, 
thus leading to increased metabolic stress in atrial myocardium. If the additive effects of 
increased diastolic blood pressure and impaired fasting glucose suggested by this analysis 
can be confirmed, one could even speculate that AF is an early manifestation of increased 
atrial work load combined with suboptimal energy provision in the atria.  
Common gene variants are strongly associated with AF 11, including in Asian populations. 
Especially in young and otherwise healthy populations, heritable factors are expected to add 
to AF risk. It is therefore tempting to speculate that a genomic predisposition in the 
population studied by Lee et al contributed to AF risk in interaction with an impaired fasting 
glucose or elevated diastolic blood pressure. PITX2, the gene that is closest to the strongest 
genomic variants associated with AF 11, 12, controls genes regulating cellular metabolism 13, 14 
and regulates the cardiac response to ischemia 15, leading to distinct atrial 
electrophysiological changes including AF 16. Further translational studies are needed to 
characterise the interactions and regulatory networks predisposing to AF when challenged 
with increased atrial pressure or altered cellular metabolism. 
In addition to that mentioned above, other novel factors that require consideration include 
obstructive sleep apnoea, physical inactivity, alcohol excess, and increased aortic stiffness. 
What has become apparent is that it is important to undertake a meticulous evaluation for all 
culprit risk factors and to treat all potential risk factors in a given individual.17 Equally the 
manner in which this intervention is delivered will be an important determinant of the 
implementation of change. There is a growing body of evidence to highlight the importance 
of an integrated patient centric care to allow individualised and target driven delivery of 
service to improve outcomes.1, 17  
This elegant population-based analysis of healthy Korean subjects delineates distinct 
predisposing factors that lead to AF in different populations associated with obesity, elevated 
diastolic blood pressure, or impaired fasting glucose. This underpins the concept that 
different forms of AF will require different interventions for successful rhythm control 
management. 18 Dr. Lee and colleagues underpin a role of weight loss in obese populations, 
and of blood pressure control in those with elevated diastolic blood pressures, and of 
restoring normal cellular glucose metabolism in the prevention of AF. Their study highlights 
the need to identify appropriate treatment targets for a given individual and potentially 
raises the possibility that these targets may differ based on the milieu of risk factors 
individual harbours. Potentially, different patients with AF will benefit from different 
interventions to prevent recurrent AF, as already shown in obese AF patients. Thereby, this 
analysis proposes an avenue towards stratified rhythm control therapy in patients with AF as 
well as underpinning stratified prevention. In addition, the data call for research, e.g. into 
the mechanisms linking AF to impaired glucose tolerance in the absence of obesity.   
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